Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Small Cell Lung Carcinoma 8Neuroblastoma 5Rhabdoid Tumor 3Ovarian Neoplasms 3Neoplasms 3Fallopian Tube Neoplasms 3Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Thrombocythemia, Essential 1Sarcoma, Ewing 1Sarcoma 1SCLC 1Rhabdomyosarcoma 1Retinoblastoma 1Recurrence 1Primary Myelofibrosis 1Polycythemia Vera 1Pancreatic Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Medulloblastoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Fallopian Tube Mucinous Adenocarcinoma 1Epilepsy 1Diffuse Intrinsic Pontine Glioma 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

Topotecan 1Surgical Procedures, Operative 1LY3295668 erbumine 1Ketamine 1Fentanyl 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Epilepsy × Topotecan × Clear all
NCT04106219 2026-04-21

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Eli Lilly and Company

Phase 1 Active not recruiting
71 enrolled
CNS

Epilepsy, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡